Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,124.35
(
0.21%
)
US TECH 100
25,895.20
(
0.09%
)
Dow Jones
49,802.47
(
0.72%
)
Brent Oil
91.82
(
1.26%
)
Bitcoin
75,824.10
(
-0.09%
)
News Focus
News Focus
Post# of 257432
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 252727

Friday, 10/04/2024 12:04:23 PM

Friday, October 04, 2024 12:04:23 PM

Post# of 257432
FDA approves EXAS’ Cologuard Plus*—a follow-on to Cologuard to be launched in 2025:

https://www.businesswire.com/news/home/20241004761985/en

Compared to original Cologuard, Cologuard Plus has new biomarkers for (modestly) improved sensitivity/specificity and enhanced stabilizers to allow patients more time to return their samples to EXAS’ lab for analysis. One glitch with original Cologuard has been a relatively high rate of invalid test results due to the patients’ not returning their samples quickly enough.

*f/k/a Cologuard 2.0.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today